Disclosed is the use of modafinil (2-[(diphenylmethyl)sulfinyl)]acetamide) prepared from supercritical carbon dioxide (CO2) in the dextrorotatory enantiomer form (modafinil S) with increased dissolution and bioavailability (relative to racemic form) for treating cocaine addiction. The pharmacokinetic features of the modafinil is characterised as having a rapid release time of less than 1 hour and reduced wakefulness-promoting effects of less than 4 hours. The modafinil is to be taken in the form of a pharmaceutical composition via oral administration, each unit dose comprising 25-200 mg of modafinil S.
